At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 48 enrolled
Drug / intervention
Bexagliflozin +3 moredrug
Likely dose
Bexagliflozin 20 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1, Open-Label, Non-Randomized, Fixed-Sequence Composite Study to Evaluate the Effects of Probenecid, Rifampin, and Verapamil on the Pharmacokinetics and Pharmacodynamics of Bexagliflozin in Healthy Subjects
In Brief
A Phase 1 clinical trial evaluating Bexagliflozin, Probenecid, and 2 other interventions for Type 2 Diabetes Mellitus. Completed, enrolled 48 participants across 1 site.
Detailed Summary
The purpose of this study is to examine the drug-drug interaction when given the study drug, bexagliflozin, with three commonly prescribed medications, probenecid, verapamil or rifampin. The study is to evaluate how safe the study drug is and how well the study drug is tolerated when taken with probenecid, verapamil or rifampin.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes Mellitus
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
201820192020202120222023202420252026
Enrollment StartSep 2017
First PostedSep 2017
Primary CompletionDec 2017
TodayJul 2026
First PostedSep 28, 2017
Enrollment StartSep 27, 2017
Primary CompletionDec 6, 2017
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 8.8 years ago
Interventions
Bexagliflozindrug
Bexagliflozin 20 mg, tablet; qd
Probeneciddrug
Probenecid tablets, 500 mg; bid
Rifampindrug
Rifampin, 600 mg (2 x 300 mg capsules); qd
Verapamildrug
Verapamil hydrochloride tablet, 120 mg; qd